FutureGen Biopharmaceutical Co., Ltd. announced that the Biologics License Application (BLA) for its self‑developed FG‑M108 has been accepted by the Center for Drug Evaluation (CDE) of China’s National Medical Products Administration (NMPA), targeting the first‑line treatment of patients with CLDN18.2‑positive, HER2‑negative, PD‑L1 combined positive score (CPS) <5 locally advanced unresectable or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma.
Regulatory Milestone
| Item | Detail |
|---|---|
| Agency | CDE of the NMPA (China) |
| Filing Type | Biologics License Application (BLA) – accepted |
| Product | FG‑M108 (self‑developed) |
| Indication | First‑line treatment of CLDN18.2‑positive, HER2‑negative, PD‑L1 CPS <5 locally advanced unresectable or metastatic gastric or GEJ adenocarcinoma |
| Acceptance Date | 18 Nov 2026 |
| Next Steps | CDE technical review; potential priority review designation and approval timing not disclosed |
Drug Profile & Mechanism of Action
- Molecule: FG‑M108, a fully human IgG1 monoclonal antibody targeting CLDN18.2 – a tight‑junction protein aberrantly exposed on gastric and GEJ tumor cells.
- Mechanism: As an IgG1 antibody, FG‑M108 is designed to engage immune effector functions (e.g., ADCC/CDC) against CLDN18.2‑expressing tumor cells; specific effector engineering details were not disclosed.
- Biomarker‑Defined Population: The BLA targets the CLDN18.2‑positive, HER2‑negative, PD‑L1 CPS <5 segment – the biomarker‑negative‑for‑alternatives population with limited first‑line targeted options beyond chemotherapy.
- Combination Strategy: Studied in combination with oxaliplatin and capecitabine (CAPOX), the standard first‑line chemotherapy backbone in gastric/GEJ adenocarcinoma.
- Origin: Self‑developed by FutureGen, retaining full intellectual property ownership; licensing or partnership arrangements were not disclosed.
Clinical Evidence – Pivotal Phase III Study (CTR20233813 / NCT06177041)
| Endpoint | Result (FG‑M108 + CAPOX) | Comparator (Placebo + CAPOX) | Relative Benefit |
|---|---|---|---|
| Progression‑Free Survival (Primary) | Significant improvement | Placebo + CAPOX | Statistically significant; magnitude not disclosed |
| Overall Survival (Key Secondary) | Significant improvement | Placebo + CAPOX | Statistically significant; magnitude not disclosed |
| Safety | Favorable safety profile; no new safety signals observed | – | Tolerable in combination with chemotherapy |
The BLA submission is based on the first interim analysis results of the pivotal Phase III study (CTR20233813, NCT06177041), in which FG‑M108 combined with CAPOX achieved significant improvements in the primary endpoint of PFS and the key secondary endpoint of OS compared with placebo plus CAPOX, with a favorable safety profile and no new safety signals observed. Hazard ratios, median survival values, and enrollment size were not disclosed in the announcement.
Market Impact & Outlook
- Gastric Cancer Landscape: Gastric and GEJ adenocarcinoma remains a leading cancer burden in China; the CLDN18.2‑positive, HER2‑negative, PD‑L1 CPS <5 subgroup has been the hardest first‑line segment to address with targeted therapy, making FG‑M108’s OS win strategically significant.
- Competitive Positioning: Achieving significant improvements in both PFS and OS against placebo plus CAPOX positions FG‑M108 within the emerging CLDN18.2 class – now one of the most contested targets in gastrointestinal oncology – with the potential to compete for first‑line standard‑of‑care status.
- Interim‑Analysis Basis: Filing on a first interim analysis accelerates time‑to‑market but leaves later data maturation as a watchpoint for label strength and payer confidence.
- Commercial Outlook: Should the BLA be approved, FG‑M108 would enter a large first‑line market; pricing, NRDL negotiation strategy, launch timing, and manufacturing capacity were not disclosed.
- Company Milestone: BLA acceptance marks FutureGen’s progression from clinical‑stage to registration‑stage biopharmaceutical company; future financing or partnership plans were not disclosed.
Forward‑Looking Statements
This brief contains forward‑looking statements regarding the CDE review of the FG‑M108 BLA, potential approval, and commercialization in first‑line CLDN18.2‑positive gastric or GEJ adenocarcinoma. Actual results may differ due to risks including regulatory review outcomes, confirmatory data maturation, competitive dynamics in the CLDN18.2 class, pricing and reimbursement negotiations, and manufacturing scale‑up.-Fineline Info & Tech
